



Medical Microbiology

Modified Carba NP test for the detection of carbapenemase production in gram-negative rods: optimized handling of multiple samples

Eloiza H. Campana^{*,1}, Stephanie G. Chuster¹, Isadora R. da Silva, Raphael P. Paschoal, Raquel R. Bonelli, Beatriz M. Moreira, Renata C. Picão

Universidade Federal do Rio de Janeiro, Instituto de Microbiologia Paulo de Góes, Laboratório de Investigação em Microbiologia Médica, Rio de Janeiro, Brazil

ARTICLE INFO

Article history:

Available online 7 December 2016

Associate Editor: Ana Lucia Darini

Keywords:

Carbapenemases

Diagnostics

Gram-negative bacteria

ABSTRACT

The modified Carba NP test presented here may be a valuable tool for laboratories interested in investigating a large number of carbapenemase-producing bacteria in a less-costly way. The test was evaluated against 48 carbapenemase-producing and carbapenemase-non-producing gram-negative bacteria. No false-positive results were obtained, but false-negative results were observed with OXA-23- and GES-carbapenemase-producing isolates. *Aeromonas* sp. are not testable by Modified Carba NP.

© 2016 Sociedade Brasileira de Microbiologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

The spread of carbapenemase-producing isolates in hospital settings is a major public health concern. Early detection of carbapenemase producers is essential to assure adequate therapy and favorable outcomes.^{1–5} Carba NP test emerged as a useful alternative to detect carbapenemase production in Enterobacteriaceae, *Pseudomonas* spp. and *Acinetobacter* spp.,^{2,6,7} as recommended by the Clinical and Laboratory Standards Institute (CLSI).⁸ The test is based on acidification of phenol red when imipenem is hydrolyzed, evidenced by the color change of the test solution from red to yellow. Carba NP test advantages over a number of other phenotypic tests

include speed in providing results, simplicity of execution, objectiveness in interpretation and increased sensitivity and specificity.^{1,2,9,10} On the other hand, sample processing may become expensive and time consuming if a large number of isolates are tested. Here we propose modifications to make the test faster and less expensive. Modifications included the omission of the centrifugation step, cell disruption using bath sonication and the use of imipenem/cilastatin as the substrate.

We studied 48 isolates, including negative controls and Enterobacteriaceae, *Pseudomonas aeruginosa*, *Acinetobacter*

* Corresponding author at: Instituto de Microbiologia, Universidade Federal do Rio de Janeiro, Cidade Universitária, Av. Carlos Chagas Filho, 373 – Centro de Ciências da Saúde, Bloco I, Rio de Janeiro, RJ 21941-902, Brazil.

E-mail: elocampana@gmail.com (E.H. Campana).

¹ These authors contributed equally to this work.

<http://dx.doi.org/10.1016/j.bjm.2016.09.015>

1517-8382/© 2016 Sociedade Brasileira de Microbiologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).



CrossMark

Table 1 – Isolates tested, modified Carba NP results and protein concentration.

Isolates	Species ^a	Beta-lactamase (Amber class) ^b	Modified Carba NP test result	Protein concentration ($\mu\text{g/mL} \pm \text{standard}$ deviation) ^c	Highest dilution yielding positive result
Carbapenemase producers	1 Klebsiella pneumoniae	KPC-2 (A)	Positive	<20 ± 5.48	1:128
	2 Kluyvera sp.	KPC-2 (A)	Positive	<20 ± 2.04	1:128
	3 Citrobacter sp.	KPC-2 (A)	Positive	<20 ± 2.31	1:256
	4 Enterobacter cloacae	KPC-2 (A)	Positive	107.39 ± 2.45	1:16
	5 Enterobacter cloacae	KPC-2 (A)	Positive	35.73 ± 21.13	1:64
	6 Klebsiella pneumoniae	KPC-2 (A)	Positive	<20 ± 12.14	1:64
	7 Aeromonas sp.	KPC-2 (A)	Inconclusive ^d	–	–
	8 Aeromonas sp.	KPC-like (A)	Inconclusive	–	–
	9 Aeromonas sp.	KPC-like (A)	Inconclusive	–	–
	10 Aeromonas sp.	KPC-like (A)	Inconclusive	–	–
	11 Aeromonas sp.	KPC-like (A)	Inconclusive	–	–
	12 Aeromonas sp.	KPC-like (A)	Inconclusive	–	–
	13 Enterobacter aerogenes	KPC-2 (A)	Positive	24.42 ± 3.8	1:8
	14 Pseudomonas aeruginosa	SPM-1 (B)	Positive	138.09 ± 4.36	1:32
	15 Pseudomonas aeruginosa	SPM-1 (B)	Positive	78.81 ± 4.81	1:64
	16 Pseudomonas aeruginosa	VIM-1 (B)	Positive	397.27 ± 24.29	1:8
	17 Acinetobacter baumannii	SIM-1 (B)	Positive	<20 ± 0.45	1:32
	18 Pseudomonas aeruginosa	GIM-1 (B)	Positive	63.3 ± 2.61	1:128
	19 Klebsiella pneumoniae	NDM-1 (B)	Positive	<20 ± 1.15	1:512
	20 Klebsiella pneumoniae	IMP-1 (B)	Positive	<20 ± 7.92	1:512
	21 Pseudomonas aeruginosa	IMP-18 (B)	Positive	177.15 ± 19.05	1:64
	22 Acinetobacter baumannii	OXA-24 (D)	Positive	570.85 ± 20.56	Undiluted
	23 Klebsiella oxytoca	OXA-48 (D)	Positive	583.22 ± 16.49	Undiluted
	24 Acinetobacter sp.	OXA-58 (D)	Positive	1045.91 ± 76.27	Undiluted
	25 Acinetobacter baumannii	OXA-143 (D)	Positive	452.67 ± 26.04	Undiluted
	26 Acinetobacter baumannii	OXA-23 (D) ^e	Negative	–	–
	27 Acinetobacter baumannii	OXA-23 (D) ^f	Negative	–	–
	28 Enterobacter cloacae	GES-5 (A)	Negative	–	–
	29 Enterobacter cloacae	GES-5 (A)	Negative	–	–
	30 Klebsiella pneumoniae	GES-16 (A)	Negative	–	–
	31 Enterobacter cloacae	GES-16 (A)	Negative	–	–
	32 Enterobacter cloacae	GES-16 (A)	Negative	–	–
Carbapenemase non- producers	C1 Pseudomonas aeruginosa	GES-1 (A)	Negative	–	–
	C2 Klebsiella pneumoniae	CTX-M-2 (A)	Negative	–	–
	C3 Pseudomonas aeruginosa	OXA-18 (D)	Negative	–	–
	C4 Escherichia coli	DHA-1 (C)	Negative	–	–
	C5 Escherichia coli	CTX-M-15 (A)	Negative	–	–
	C6 Escherichia coli	CTX-M-8 (A)	Negative	–	–
	C7 Escherichia coli	FOX-5 (C)	Negative	–	–
	C8 Escherichia coli	MIR-1 (C)	Negative	–	–
	C9 Escherichia coli	TEM-1 (A)	Negative	–	–
	C10 Aeromonas sp.	GES-like (A)	Inconclusive	–	–
	C11 Aeromonas sp.	GES-like (A)	Inconclusive	–	–
	C12 Aeromonas sp.	None	Inconclusive	–	–
	C13 Aeromonas sp.	None	Inconclusive	–	–
	C14 Aeromonas sp.	None	Inconclusive	–	–
	C15 Pseudomonas aeruginosa ATCC	None	Negative	–	–
	C16 Escherichia coli J53	None	Negative	–	–

^a Identification determined by MALDI-TOF MS (Bruker, Germany).^b β -Lactamases production was assessed by PCR and sequencing assays.^c At the least diluted sample showing positive result.^d Inconclusive: red-to-yellow color change was observed in both imipenem – and + solutions.^e This isolate show ISAb-1 positioned upstream and in the opposite transcriptional direction of bla_{OXA-23}.^f This isolate does not show ISAb-1 positioned upstream bla_{OXA-23}.

baumannii and *Aeromonas* spp. producing class A, B or D carbapenemases (Table 1). Bacterial strains were cultivated onto Trypticase soy agar (TSA) (Difco Laboratories) at 37 °C for 18–24 h. A 10 μL calibrated loopfull of the test strain was inoculated into 500 μL Tris-HCl (20 mM-pH 7.5) (Invitrogen). The

suspension was subjected to vortex homogenization and bath sonication for 30 min (BRANSONIC ULTRASONIC CLEANER, 47 kHz ± 6%, 60 W) and preserved on ice. Then, 30 μL of the cell extract was mixed with 100 μL of phenol red (Isofar) containing 0.1 mM ZnSO₄ (Merck) (imipenem –) and 100 μL phenol red

containing 0.1 mM ZnSO₄ and 6 mg/mL imipenem/cilastatin (Merck) (imipenem +). The mixtures were incubated at 37 °C for 2 h. Tests were performed in duplicate for all isolates. The color change of the imipenem-containing vial from red to yellow or orange indicated a positive result. Three independent observers recorded the results with no discordant readings.

To assess the inferior limit of carbapenemase detection by the modified Carba NP proposed, the test was also performed using diluted crude extracts. The last dilution yielding positive result was centrifuged and the supernatant was subjected to total protein quantification, which was performed in triplicate using the Pierce™ BCA Protein Assay Kit (Thermo Scientific) following the manufacturer's recommendations.

Sensitivity, specificity, positive and negative predictive values (SN, SP, PPV and NPV, respectively) were calculated, excluding *Aeromonas* spp. PCR results for carbapenamases were considered the gold standard. SN, SP, PPV, and NPV were calculated with the formulas $a/(a+c)$, $d/(b+d)$, $a/(a+b)$ and $d/(c+d)$, respectively.

Most carbapenemase-producing isolates showed the expected positive result, indicating that the modification in the extraction protocol did not jeopardize the sensitivity of the test (Table 1). Protein concentrations at the most diluted extract showing carbapenemase activity varied from <20 µg/mL to 1045.92 µg/mL (Table 1).

All KPC producing isolates yielded positive results except for *Aeromonas* sp. (Table 1) which showed inconclusive results in repeated tests irrespective of the beta-lactamase produced, as the red-to-yellow color change was observed in solutions imipenem – and + (Fig. 1). This finding was related to the acidic nature of the crude extract assessed in repeated assays (pH = 5.5). Although *Aeromonas* spp. producing acquired carbapenemases are not common causes of multidrug-resistant infections, microbiologists should be aware that Carba NP test might not be suitable to investigate carbapenemase production in these bacteria. All metalo-β-lactamase (MBL) producers showed positive results at the modified Carba NP test, as expected. Of notice, MBL-producing *P. aeruginosa* required increased protein levels in crude extracts to generate positive results, likely due to difficulty in disrupting the cell wall of such isolates. In agreement with previous work,^{2,11,12} all GES-like carbapenemase producing isolates showed negative results. Most class D carbapenemase producing isolates showed positive results in Modified Carba NP test, except those producing OXA-23 (Table 1). Diluted cell extracts, however, showed negative results, which is consistent with the decreased imipenem catalytic activity presented by oxacillinas compared to other carbapenemases. Isolates carrying bla_{OXA-23} showed negative results, regardless of the presence or absence of ISA_{Ba1} upstream this gene. The SN, SP, PPV, and NPV for Carba NP modified were 73.1, 100, 100 and 61.1%, respectively. Positive results were observed at different times for different carbapenemases (ranging from 5 min for NDM and KPC to 2 h for OXA type).

Noteworthy, the Modified Carba NP test gave indistinguishable results when performed using cell extracts obtained by probe sonication (data not shown). Despite the fact that the equipment for bath sonication is cheaper than the probe-based, it also enables processing a large number of isolates concomitantly and avoids excessive manipulation




Fig. 1 – Representative results of the modified Carba NP test. Non-carbapenemase producers (A, B, H and K), carbapenemase producers (C, F, G, I, J, L, M, and O), and *Aeromonas* spp. isolates (D, E, K, N and P) with negative control solutions (–) and test solution (+). (A) *E. coli* J-53; (B) *P. aeruginosa* ATCC 25922; (C) KPC-2-producing *E. cloacae*; (D) KPC-like-producing *Aeromonas* sp. (E) KPC-like-producing *Aeromonas* sp. (F) NDM-1-producing *K. pneumoniae*; (G) OXA-48-producing *K. oxytoca*; (H) CTX-M-15-producing *E. coli*; (I) OXA-23-producing *A. baumannii*; (J) OXA-143-producing *A. baumannii*; (K) *Aeromonas* sp. (L) IMP-18-producing *P. aeruginosa*; (M) SPM-1-producing *P. aeruginosa*; (N) KPC-like-producing *Aeromonas* sp. (O) GES-16-producing *E. cloacae*; (P) GES-like-producing *Aeromonas* sp.

of potential carbapenemase producers in high inoculums, protecting against environment contamination.

Although other studies have made different changes in Carba NP,^{13–15} the Modified Carba NP test presented here may be a valuable tool for laboratories interested in investigating several carbapenemase-producing bacteria with decreased cost. Although these modifications involve the acquisition of a sonication apparatus, its initial cost is counterbalanced by the ability to process several isolates concomitantly and by the elimination of the lysis buffer, which is especially attractive for laboratories that must import this expensive reagent. We also reinforce that imipenem/cilastatin available in hospital

pharmacies may serve as the substrate for the Modified Carba NP test, representing an off-label use of this medication in institutions where this practice is allowed.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgments

We are grateful to Ana Cristina Gales, Laurent Poirel and Marise Dutra Asensi for providing positive controls employed in this study. This work was supported by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ).

REFERENCES

1. Doret L, Poirel L, Nordmann P. Rapid detection of carbapenemase-producing *Pseudomonas* spp. *J Clin Microbiol.* 2012;50:3773–3776.
2. Doret L, Poirel L, Nordmann P. Rapid identification of carbapenemase types in *Enterobacteriaceae* and *Pseudomonas* spp. by using a biochemical test. *Antimicrob Agents Chemother.* 2012;56:6437–6440.
3. Giske CG, Gezelius L, Samuelsen Ø, Warner M, Sundsfjord A, Woodford N. A sensitive and specific phenotypic assay for detection of metallo-β-lactamases and KPC in *Klebsiella pneumoniae* with the use of meropenem disks supplemented with aminophenylboronic acid, dipicolinic acid and cloxacillin. *Clin Microbiol Infect.* 2011;7:552–556.
4. Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of *Klebsiella pneumoniae* carbapenemases. *Lancet Infect Dis.* 2013;13:785–796.
5. Picão RC, Andrade SS, Nicoletti AG, et al. Metallo-β-lactamase detection: comparative evaluation of double-disk synergy versus combined disk tests for IMP-, GIM-, SIM-, SPM-, or VIM-producing isolates. *J Clin Microbiol.* 2008;46:2028–2037.
6. Doret L, Poirel L, Errera C, Nordmann P. CarbAcinet NP test for rapid detection of carbapenemase-producing *Acinetobacter* spp. *J Clin Microbiol.* 2014;52:1364–2359.
7. Doret L, Poirel L, Nordmann P. Further proofs of concept for the Carba NP test. *Antimicrob Agents Chemother.* 2014;58:1269.
8. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-fifth Informational Supplement M100-S25. Wayne, PA, USA: Clinical and Laboratory Standards Institute; 2015.
9. Doret L, Bréhard L, Poirel L, Nordmann P. Impact of the isolation medium for detection of carbapenemase-producing *Enterobacteriaceae* using an updated version of the Carba NP test. *J Med Microbiol.* 2014;63:772–776.
10. Vasoo S, Cunningham S, Kohner PC, et al. Comparison of a novel, rapid chromogenic biochemical assay, the Carba NP test, with the modified Hodge test for detection of carbapenemase-producing gram-negative bacilli. *J Clin Microbiol.* 2013;51:3097–3101.
11. Osterblad M, Hakanen AJ, Jalava J. Evaluation of the Carba NP test for carbapenemase detection. *Antimicrob Agents Chemother.* 2014;58:7553–7556.
12. Tijet N, Boyd D, Patel SN, Mulvey MR, Melano RG. Evaluation of the Carba NP test for rapid detection of carbapenemase-producing *Enterobacteriaceae* and *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother.* 2013;57:4578–4580.
13. Bakour S, Garcia V, Loucif L, et al. Rapid identification of carbapenemase-producing *Enterobacteriaceae*, *Pseudomonas aeruginosa* and *Acinetobacter baumannii* using a modified Carba NP test. *New Microbes New Infect.* 2015;7:89–93.
14. Pasteran F, Tijet N, Melano RG, Corso A. A simplified protocol of the Carba NP test for enhanced detection of carbapenemase producers direct from bacterial cultures. *J Clin Microbiol.* 2015;53:3908–3911.
15. Pires J, Novais Á, Peixe L. Blue-Carba, an easy biochemical test for detection of diverse carbapenemase producers directly from bacterial cultures. *J Clin Microbiol.* 2013;51:4281–4283.